SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-258997
Filing Date
2023-10-19
Accepted
2023-10-19 09:29:01
Documents
13
Period of Report
2023-10-18
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d864803d8k.htm   iXBRL 8-K 27036
2 EX-10.1 d864803dex101.htm EX-10.1 1106359
  Complete submission text file 0001193125-23-258997.txt   1488495

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20231018.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20231018_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20231018_pre.xml EX-101.PRE 10817
7 EXTRACTED XBRL INSTANCE DOCUMENT d864803d8k_htm.xml XML 3445
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 231333552
SIC: 2834 Pharmaceutical Preparations